How much are you willing to pay to avoid lockdowns? Evidence from the real estate market
Real Estate Economics · 24.03.2026
DOI: 10.1111/1540-6229.70044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Real Estate Economics, online erschienen am 24.03.2026. Verfasst von Jian Liang und 2 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In response to the COVID‐19 pandemic, numerous countries implemented lockdowns. In Victoria, Australia, a unique two‐tier system was employed, segregating areas with a Ring of Steel boundary and imposing additional restrictions within. This study focuses on the impact of lockdowns on housing prices and rents, exploring whether people are willing to pay a premium to live in areas with fewer lockdown restrictions and thus proposing this premium as an alternative measure of lockdown cost. We utilized a spatial difference‐in‐differences design to test on the lockdown boundary area and address many confounding factors. The research reveals a 7%–8% relative drop in housing rents within the Ring of Steel, dissipating within 6 months after lockdowns ended. A surprisingly large drop of 6%–7% in housing values is observed inside the Ring of Steel. These empirical estimates suggest homebuyers’ behavioral biases could further depress housing values during a pandemic.
Zitieren
APA
Liang, J., Lee, C. L., & Li, Q. (2026). How much are you willing to pay to avoid lockdowns? Evidence from the real estate market. Real Estate Economics. https://doi.org/10.1111/1540-6229.70044
Vancouver
Liang J, Lee CL, Li Q. How much are you willing to pay to avoid lockdowns? Evidence from the real estate market. Real Estate Economics. 2026. doi:10.1111/1540-6229.70044
BibTeX
@article{Liang2026,
author = {Liang, Jian and Lee, Chyi Lin and Li, Qiang},
title = {How much are you willing to pay to avoid lockdowns? Evidence from the real estate market},
journal = {Real Estate Economics},
year = {2026},
doi = {10.1111/1540-6229.70044}
}
EUVIMED